Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Blinded Randomized Parallel Trial to Define the ECG Effects of Bardoxolone Methyl Using a Clinical and a Supratherapeutic Dose Compared to Placebo and Moxifloxacin (a Positive Control) in Healthy Men and Women: A Thorough ECG Trial.

NCT01689116 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT01689116
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01689116 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Blinded Randomized Parallel Trial to Define the ECG Effects of Bardoxolone Methyl Using a Clinical and a Supratherapeutic Dose Compared to Placebo and Moxifloxacin (a Positive Control) in Healthy Men and Women: A Thorough ECG Trial.
Lead sponsor
Biogen
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2012
Completion date
November 30, 2012
Enrollment
179 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers